<DOC>
	<DOCNO>NCT02167620</DOCNO>
	<brief_summary>Schizophrenia associate lifespan shorten 20 year , due cardiovascular disease ( CVD ) , antipsychotic ( AP ) medication understand contribute risk associate metabolic side-effects . Metformin , medication use treat prediabetes , diabetes general population , hold promise regard reduction AP-related metabolic problem , directly test early episode patient beyond weight loss , specifically patient diabetes prediabetes psychosis . We propose replicate finding metformin reduce weight gain , dysglycemia uniquely focus early episode population diagnose prediabetes diabetes . To help determine long-term risk/benefit adjunctive metformin , propose look change abdominal liver fat , two well-established risk factor CVD . Given link dysglycemia , obesity hippocampal volume loss cognitive dysfunction , explore improvement metabolic index associate change cognition brain structure .</brief_summary>
	<brief_title>Metformin Co-morbid Diabetes Prediabetes Serious Mental Illness</brief_title>
	<detailed_description>This 16 week , double-blind , randomize pilot study , propose recruit 24 patient schizophrenia , schizoaffective disorder ( DSM 5 ) , overweight obese ( BMI &gt; 25 ) prediabetes type 2 diabetes . Randomization occur 2:1 basis , 16 patient randomised metformin , 8 placebo . Metfomin/placebo dispense monthly . The baseline /or screen visit include physical exam ( include anthropometric measure ) , medical history , fast blood work ( glucose , insulin , HbA1c , lipid , electrolyte , thyroid , liver/kidney function ) , addition urine drug screen . Women child-bearing age give pregnancy test . Patients meet inclusion criterion consent study oral glucose tolerance test ( OGTT ) , baseline abdominal brain MRI ( respectively assess visceral adiposity , key risk factor CV disease , hippocampal volume ) . Anthropometric measure pill count repeat bi-weekly . At week 8 , fast insulin/glucose , HbA1C , liver function test measure . End study measure ( week 16 ) , include panel bloodwork conduct baseline , well repeat OGTT , abdominal brain MRI . Rountine psychopathology scale , include BPRS , CGI , CDS measure baseline , week 16 . The Brief Assessment Cognition Schizophrenia ( BACS ) also complete baseline , study end .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients within 5 year diagnosis schizophrenia , schizoaffective disorder , bipolar disorder ( DSM V ) , young 40 year old , regardless duration illness Comorbid diagnosis prediabetes diabetes ( Canadian American Diabetes Association criterion ) Patients comorbid axis , nicotine dependence , cannabis abuse Patients liver , renal dysfunction , Patients positive drug urine screen ( cannabis nicotine ) Females positive pregnancy test exclude . Prior trial metformin , report lack tolerability Patients A1C &gt; 9.5 % , symptomatic hyperglycemia metabolic decompensation</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>